Deutsche Bank AG Analysts Give MorphoSys AG (MOR) a €90.00 Price Target
MOR has been the subject of a number of other reports. J P Morgan Chase & Co set a €85.00 ($100.00) price objective on shares of MorphoSys AG and gave the stock a buy rating in a report on Friday, October 6th. Commerzbank Ag set a €76.00 ($89.41) price objective on shares of MorphoSys AG and gave the stock a buy rating in a report on Tuesday, October 24th. Goldman Sachs Group, Inc. (The) set a €55.00 ($64.71) price objective on shares of MorphoSys AG and gave the stock a neutral rating in a report on Thursday, September 7th. Berenberg Bank set a €85.00 ($100.00) price objective on shares of MorphoSys AG and gave the stock a buy rating in a report on Thursday, October 19th. Finally, Independent Research GmbH set a €84.00 ($98.82) price objective on shares of MorphoSys AG and gave the stock a buy rating in a report on Wednesday, October 4th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company currently has an average rating of Buy and a consensus price target of €79.00 ($92.94).
ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://theolympiareport.com/2017/11/02/deutsche-bank-ag-analysts-give-morphosys-ag-mor-a-90-00-price-target.html.
About MorphoSys AG
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Ratings for MorphoSys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys AG and related companies with Analyst Ratings Network's FREE daily email newsletter.